Professional Summary
Professional Overview
David Karabelnik is a highly accomplished life sciences serial entrepreneur, biochemist, and corporate finance specialist based in Zürich, Switzerland. As the Owner of BRESLIN AG and BRESLIN BIOTECH AG, he leverages his extensive expertise in spin-offs, young company developments, and entrepreneurship to drive innovation and growth within the life sciences industry.
Experience Summary
Current Role
As the Owner of BRESLIN AG and BRESLIN BIOTECH AG, David Karabelnik is responsible for overseeing the strategic direction and operations of these dynamic life sciences companies. In this capacity, he draws upon his extensive background as a serial entrepreneur, biochemist, and corporate finance specialist to guide the development and commercialization of innovative products and technologies.
Career Progression
Prior to his current roles, David Karabelnik has demonstrated a remarkable track record as a founder and serial entrepreneur. He has been instrumental in the establishment and support of various spin-offs and young company developments, including ANAWA (CH), AMYPOPHARMA (IT), MEMO THERAP (CH), and QITHERA (D), among others. His ability to identify and capitalize on emerging opportunities has been a key driver of his success in the life sciences industry.
Academic Background
David Karabelnik holds a strong academic background, with a focus on biochemistry. His specialized knowledge and expertise in this field have been instrumental in shaping his professional success and contributions to the life sciences industry.
Areas of Expertise
Throughout his distinguished career, David Karabelnik has developed a diverse set of skills and expertise, including:
- Life sciences entrepreneurship and serial venture creation
- Biochemistry and scientific research
- Corporate finance and strategic business development
- Spin-off and young company support and growth
Professional Impact
David Karabelnik's impact on the life sciences industry is evident through his involvement in numerous successful ventures and his ability to identify and capitalize on emerging opportunities. His entrepreneurial acumen, combined with his technical and financial expertise, has enabled him to drive innovation and foster the growth of multiple companies within the sector.
Conclusion
As a life sciences serial entrepreneur, biochemist, and corporate finance specialist, David Karabelnik continues to make significant contributions to the industry. With his extensive experience, specialized knowledge, and proven track record of success, he is well-positioned to continue driving innovation and growth within the dynamic and ever-evolving life sciences landscape.
